IndustryCompany release

Mesoblast appoints interim COO as it prepares rexlemestrocel-L filings in heart failure and back pain

Mesoblast Ltd (MESO) · Thu 12 Nov 2026

Dr Gregory George will act as interim chief operating officer while Mesoblast aligns with the FDA on a BLA in LVAD patients and awaits Phase 3 back pain data.

Mesoblast said on 9-10 November 2026 that it is widening its operational management team to prepare for commercial scale-up of rexlemestrocel-L, its cell therapy candidate for chronic low back pain (CLBP) and cardiovascular disease.

Dr Gregory George will serve as interim chief operating officer while the company searches for a permanent appointee. Dr Eric Rose will concentrate on his duties as chief medical officer and will leave the Board.

On the regulatory front, Mesoblast said it has aligned with the US Food and Drug Administration on a Biologics License Application (BLA) for rexlemestrocel-L. The proposed indication is reducing major gastrointestinal bleeding in patients with end-stage heart failure who are supported by a left ventricular assist device (LVAD).

The company also expects the Phase 3 readout in chronic low back pain in the second half of 2027. The material available does not give a filing date for the LVAD bleeding BLA or further trial detail.

What it means for your team

  • The stated FDA alignment on a BLA for LVAD-related GI bleeding signals a possible regulatory submission, though no timing was disclosed.
  • The CLBP Phase 3 readout, expected in H2 2027, is the next key clinical milestone for the programme.
  • Commercial scale-up planning, including the COO search, suggests manufacturing, supply and launch-readiness work is under way; teams tracking cell therapy supply should watch for further detail.

Company's press release (SEC filing): Mesoblast Ltd ↗

Article written by VigiEye from the official source (Mesoblast Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →